More dra­ma ahead: Sarep­ta plans to file for ac­cel­er­at­ed Duchenne ap­proval, with ad­comm a 'n­ear cer­tain­ty'

While Sarep­ta has three an­ti­sense oligonu­cleotide ther­a­pies ap­proved — al­beit not with­out con­tro­ver­sy — for Duchenne mus­cu­lar dy­s­tro­phy, it has been work­ing on a long-term treat­ment in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER